BioNTech Company Insiders

BioNTech's latest congressional trading

BioNTech Management Team Effectiveness

The company has return on total asset (ROA) of (0.023) % which means that it has lost $0.023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0304) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.03 in 2026. Return On Capital Employed is likely to rise to -0.06 in 2026. At this time, BioNTech's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.1 B in 2026, whereas Non Currrent Assets Other are likely to drop slightly above 37.7 M in 2026. Net Income Applicable To Common Shares is likely to rise to about 12.4 B in 2026, whereas Common Stock Shares Outstanding is likely to drop slightly above 233 M in 2026. BioNTech holds a total of 250.93 Million outstanding shares. BioNTech SE retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On September 12, 2025, Representative Valerie Hoyle of US Congress acquired under $15k worth of BioNTech SE's common stock. Some institutional investors establish a significant position in stocks such as BioNTech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioNTech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BioNTech Workforce Comparison

The company has Profit Margin (PM) of (0.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02.

BioNTech SE Benchmark Summation

BioNTech Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BioNTech SE often depends on how effective the management is. BioNTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioNTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioNTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in BioNTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioNTech SE. Check BioNTech's Beneish M Score to see the likelihood of BioNTech's management manipulating its earnings.

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.